# Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

> **NCT00217698** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 63 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gefitinib
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00217698
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217698, "Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00217698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*